High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Guedes, Joana G ^a   Veiga, Isabel ^a   Rocha, Patrícia ^a   Pinto, Pedro ^a   Pinto, Carla ^a   Pinheiro, Manuela ^a   Peixoto, Ana ^a   Fragoso, Maria ^a   Raimundo, Ana ^a   Ferreira, Paula ^a   Machado, Manuela ^a   Sousa, Nuno ^a   Lopes, Paula ^a   Araújo, António ^b   Macedo, Joana ^b   Alves, Fernando ^c   Coutinho, Camila ^d   Henrique, Rui ^a,e   Santos, Lúcio L ^a   Teixeira, Manuel R ^a,e  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b S Sebastião Hospital   (Portugal)

^c Trás os Montes e Alto Douro Central Hospital   (Portugal)

^d Alto Ave Hospital Center ^*  (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; B RAF KINASE GENE; CANCER STAGING; CODON; COLON MUCOSA; COLORECTAL CARCINOMA; EXON; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PIK3CA GENE; RECTUM; SIGMOID; TUMOR GENE; WILD TYPE;

ADULT; BASE SEQUENCE; COLORECTAL NEOPLASMS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; NEOPLASM METASTASIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSITION TEMPERATURE; TREATMENT OUTCOME;

EID: 84875483113     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-169     Document Type: Article

References (51)

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353(2):172-187. 10.1056/NEJMra044389, 16014887.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2009, 360(15):1579.
3. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004, 10(8):789-799. 10.1038/nm1087, 15286780.
4. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50(1):113-130. 10.1111/j.1365-2559.2006.02549.x, 17204026.
5. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26(22):3291-3310. 10.1038/sj.onc.1210422, 17496923.
6. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(10):1626-1634. 10.1200/JCO.2007.14.7116, 18316791.
7. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chien CRC, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417. 10.1056/NEJMoa0805019, 19339720.
8. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):663-671. 10.1200/JCO.2008.20.8397, 19114683.
9. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359(17):1757-1765. 10.1056/NEJMoa0804385, 18946061.
10. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, Erdkamp FLG, Vos AH, van Groeningen CJ, Sinnige HAM. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360(6):563-572. 10.1056/NEJMoa0808268, 19196673.
11. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27(5):672-680. 10.1200/JCO.2008.19.8135, 19114685.
12. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169. 10.1038/sj.bjc.6603685, 2360149, 17375050.
13. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374-379. 10.1200/JCO.2007.12.5906, 18202412.
14. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19(3):508-515.
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954. 10.1038/nature00766, 12068308.
16. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113. 10.1126/science.1145720, 17932254.
17. Pinto P, Rocha P, Veiga I, Guedes J, Pinheiro M, Peixoto A, Pinto C, Fragoso M, Sanches E, Araujo A. Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genet 2011, 204(8):439-446. 10.1016/j.cancergen.2011.07.003, 21962894.
18. Lungu O, Wright TC, Silverstein S. Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. Mol Cell Probes 1992, 6(2):145-152. 10.1016/0890-8508(92)90059-7, 1355266.
19. Pearson H, Stirling D. DNA extraction from tissue. Methods Mol Biol 2003, 226:33-34.
20. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008, 130(2):247-253. 10.1309/LWDY1AXHXUULNVHQ, 18628094.
21. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 2005, 36(5):486-493. 10.1016/j.humpath.2005.03.015, 15948115.
22. Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauemhofer T, Samonigg H, Hoefler G, Dandachi N. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009, 11(2):140-147. 10.2353/jmoldx.2009.080100, 2665863, 19213871.
23. The catalogue of somatic mutations in cancer http://www.sanger.ac.uk/perl/genetics/CGP/cosmic accessed on 01/03/2012.
24. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762. 10.1016/S1470-2045(10)70130-3, 20619739.
25. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101(4):715-721. 10.1038/sj.bjc.6605177, 2736831, 19603018.
26. Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. Jpn J Clin Oncol 2011, 41(2):165-171. 10.1093/jjco/hyq173, 20926413.
27. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27(35):5924-5930. 10.1200/JCO.2008.21.6796, 19884556.
28. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712. 10.1200/JCO.2008.18.0786, 19001320.
29. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6(5):279-286. 10.1016/S1470-2045(05)70102-9, 15863375.
30. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010, 46(11):1997-2009. 10.1016/j.ejca.2010.03.036, 20413299.
31. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lievre A, Cortet M, Bouvier AM, Rat P. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008, 122(10):2255-2259. 10.1002/ijc.23388, 18224685.
32. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003, 22(57):9192-9196. 10.1038/sj.onc.1207061, 14668801.
33. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis - RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418(6901):934. 10.1038/418934a, 12198537.
34. Lurkin I, Stoehr R, Hurst CD, van Tilborg AA, Knowles MA, Hartmann A, Zwarthoff EC. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 2010, 5(1):e8802. 10.1371/journal.pone.0008802, 2809099, 20098682.
35. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S, Duval A, Carneiro F, Machado JC, Hamelin R. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005, 41(11):1649-1654. 10.1016/j.ejca.2005.04.022, 15994075.
36. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4(10):e7287. 10.1371/journal.pone.0007287, 2750753, 19806185.
37. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997, 277(5324):333-338. 10.1126/science.277.5324.333, 9219684.
38. Buhrman G, Wink G, Mattos C. Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure 2007, 15(12):1618-1629. 10.1016/j.str.2007.10.011, 2273997, 18073111.
39. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010, 70(14):5901-5911. 10.1158/0008-5472.CAN-10-0192, 2943514, 20570890.
40. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991, 349(6305):117-127. 10.1038/349117a0, 1898771.
41. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116(6):855-867. 10.1016/S0092-8674(04)00215-6, 15035987.
42. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005, 65(11):4562-4567. 10.1158/0008-5472.CAN-04-4114, 15930273.
43. Samuels Y, Wang ZH, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell DM, Riggins GJ. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670):554. 10.1126/science.1096502, 15016963.
44. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, DeLong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7(6):561-573. 10.1016/j.ccr.2005.05.014, 15950905.
45. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007, 317(5835):239-242. 10.1126/science.1135394, 17626883.
46. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 2007, 104(13):5569-5574. 10.1073/pnas.0701005104, 1838453, 17376864.
47. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110 alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008, 105(7):2652-2657. 10.1073/pnas.0712169105, 2268191, 18268322.
48. Kang SY, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005, 102(3):802-807. 10.1073/pnas.0408864102, 545580, 15647370.
49. Bader AG, Kang SY, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5(12):921-929. 10.1038/nrc1753, 16341083.
50. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007, 318(5857):1744-1748. 10.1126/science.1150799, 18079394.
51. Mao C, Liao RY, Qiu LX, Wang XW, Ding H, Chen Q. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep 2011, 38(4):2219-2223. 10.1007/s11033-010-0351-4, 20857202.